Our finding supported the Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes that GLP-1 agonists may have roles in treating type 1 diabetes in particular patients with obesity and preserving beta-cell function (43). This evidence concerns the gene GLP1R and obesity disorder.